|
|
|
|
|
|
Sponsored by: |
Pfizer |
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00035347 |
A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens. After written informed consent is obtained, patients will receive one of the following two treatment regimens: 1) intravenous administration of azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous administration of levofloxacin followed by levofloxacin tablets. At least four study visits are normally conducted up to approximately one month after starting therapy. The objective of this study is to compare the safety and efficacy of the two treatment regimens.
Condition | Intervention | Phase |
Pneumonia |
Drug: IV azithromycin Drug: Ceftriaxone Drug: Azithromycin tablets Drug: IV levofloxacin Drug: Levofloxacin tablets |
Phase IV |
MedlinePlus related topics: | Pneumonia |
Drug Information available for: | Azithromycin Ceftriaxone Ceftriaxone Sodium Levofloxacin Ofloxacin Ofloxacin hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Show 35 Study Locations |
Pfizer |
Link to ClinicalStudyResults.org Posting 
  |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A0661035 |
First Received: | May 2, 2002 |
Last Updated: | September 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00035347 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|